TAVO + Keytruda demonstrated 41% overall response rate and 36% complete response in a late-stage metastatic melanoma study featured in ‘Clinical Cancer Research’.- Oncosec Medical.
Oncosec Medical announced published data in Clinical Cancer Research that demonstrated its lead product candidate, TAVO (interleukin-12 or “IL-12” plasmid), in combination with the anti-PD-1 checkpoint inhibitor Keytruda… read more.